Royalty and Commercial Payment Purchase Agreements - Cost Recovery Method - Palobiofarma (Details) |
1 Months Ended | 3 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2019
USD ($)
|
Mar. 31, 2025
USD ($)
|
Mar. 31, 2024
USD ($)
|
Dec. 31, 2024
USD ($)
|
|
| Agreements | ||||
| Payments of consideration under RPAs, AAAs and CPPAs | $ 8,000,000 | $ 15,000,000 | ||
| Long-term royalty and commercial payment receivables under the cost recovery method | 59,916,000 | $ 55,936,000 | ||
| Palobiofarma | Royalty Purchase Agreement | ||||
| Agreements | ||||
| Number of drug candidates | 6 | |||
| Payments of consideration under RPAs, AAAs and CPPAs | $ 10,000,000 | |||
| Long-term royalty and commercial payment receivables under the cost recovery method | $ 10,000,000 | |||
| Allowance for credit losses | $ 0 | $ 0 | ||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of allowance for credit loss for right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of drug candidates under the terms of the agreement. No definition available.
|
| X | ||||||||||
- Definition Amount of cash outflow for consideration under agreements, including Royalty Purchase Agreements (RPAs), Assignment and Assumption Agreements (AAAs), Commercial payment purchase agreement (CPPAs) and other agreements classified as investing activities. Payments may include upfront payments, one-time payments, milestone payments and contingent consideration payments. No definition available.
|
| X | ||||||||||
- Definition Royalty and commercial payment receivables under cost recovery method probable and reasonably estimable to be received after one year or beyond the normal operating cycle, if longer. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|